Clicky

InMed Pharmaceuticals Inc.(INM)

Description: InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.


Keywords: Medicine Disease Cannabis Pharmacology Rare Diseases Dermatology Glaucoma Stage Pharmaceutical Toxicology Cannabinoid Genodermatoses Cannabinol Epidermolysis Bullosa Treatment Of Glaucoma Ocular Disease

Home Page: www.inmedpharma.com

INM Technical Analysis

815 West Hastings Street
Vancouver, BC V6C 1B4
Canada
Phone: 604 669 7207


Officers

Name Title
Mr. Eric A. Adams B.S. Chem., M.I.B. Pres, CEO & Director
Ms. Alexandra Diane-Janet Mancini M.Sc. Sr. VP of Clinical & Regulatory Affairs
Dr. Eric Chih-Hsien Hsu Sr. VP of Preclinical R&D
Dr. Sazzad Hossain M.Sc., Ph.D. Co-Founder
Ms. Sarah Li CPA, CGA VP of Accounting & Controller
Mr. Michael Woudenberg P.Eng. Chief Operating Officer
Colin Clancy Sr. Director of Investor Relations
Mr. Jerry P. Griffin VP of Sales & Marketing
Dr. Shane A. Johnson Ph.D. Sr. VP & GM of BayMedica
Dr. Ado Muhammad Sr. Consultant of Medical Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.1975
Price-to-Sales TTM: 1.4334
IPO Date: 2020-11-12
Fiscal Year End: June
Full Time Employees: 13
Back to stocks